N-甲基烟酰胺 | 114-33-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-甲基烟酰胺
• 英文名称: N-Methylnicotinamide
• 英文别名: methyl nicotinamide；N‐methylnicotinamide；mna；N-methylpyridine-3-carboxamide
• CAS: 114-33-0
• 化学式: C₇H₈N₂O
• mdl: MFCD00006384
• 分子量: 136.153
• InChiKey: ZYVXHFWBYUDDBM-UHFFFAOYSA-N

物化性质

• 熔点：
  102-105 °C(lit.)
• 沸点：
  250.42°C (rough estimate)
• 密度：
  1.1778 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

吸收、分配和排泄

• 消除途径

N-甲基烟酰胺通过尿液排出。

N-methylnicotinamide is excreted in the urine.

来源:DrugBank

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险性防范说明：
  P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H315,H319
• 储存条件：
  2-8°C

SDS

Name:	N-Methylnicotinamide 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	114-33-0

Section 1 - Chemical Product MSDS Name:N-Methylnicotinamide 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
114-33-0	N-Methylnicotinamide	98%	204-046-4

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 114-33-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder and chunks
Color: white to light beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 102.00 - 105.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8N2O
Molecular Weight: 136.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 114-33-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-Methylnicotinamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 114-33-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 114-33-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 114-33-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

N-甲基尼古丁胺（MNA，尼古丁甲酰胺，N-甲基-3-吡啶甲酸胺）是一种活性内源性代谢产物。它可以通过调节ADMA-DDAH轴改善内皮功能障碍并减轻动脉粥样硬化。

靶点

Human Endogenous Metabolite

反应信息

• 作为反应物：
  描述：

  N-甲基烟酰胺 在 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 水 为溶剂， 反应 9.0h， 生成 氧烟酸
  参考文献：
  名称：

  Nagano, Hiroyuki; Nawata, Yoshiharu; Hamana, Masatomo, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 10, p. 4068 - 4077

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲氧基-n-甲基烟酰胺 在 1,2-双(二苯基膦基)苯 、 三异丁基铝 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 正己烷 为溶剂， 反应 6.0h， 以79%的产率得到N-甲基烟酰胺
  参考文献：
  名称：

  Dealkoxylation of N-alkoxyamides without an external reductant driven by Pd/Al cooperative catalysis

  摘要：

  Lewis酸辅助钯催化的N-烷氧基酰胺脱烷氧化反应在无外部还原剂的情况下实现。

  DOI：

  10.1039/d0ob01815e
• 作为试剂：
  描述：

  4-羟基-6-氯喹唑啉 、 希诺米啉 在 potassium phosphate 、 N-甲基烟酰胺 、 copper(I) bromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以82.1%的产率得到4-hydroxy-6-(4,4-dimethyl-4,5-dihydrooxazol-2-amino)quinazoline
  参考文献：
  名称：

  一种妥卡替尼的制备方法

  摘要：

  本发明涉及一种妥卡替尼的制备方法，以4‑羟基‑6‑氯喹唑啉为原料，先与2‑氨基‑4,4‑二甲基‑4,5‑二氢噁唑发生铜催化的C‑N交叉偶联反应，然后采用卡特缩合剂(BOP)活化喹唑啉酮的4‑位羟基，与4‑([1,2,4]三唑并[1,5‑a]吡啶‑7‑氧基)‑3‑甲基苯胺发生亲核取代反应得到妥卡替尼。本路线避免了使用高腐蚀性、高毒试剂，对设备要求低，降低了操作难度和环保要求，产品收率高、纯度高；路线简洁环保，适合大规模生产。

  公开号：

  CN112159404B

文献信息

• N-ARYLAMIDINE-SUBSTITUTED TRIFLUOROETHYL SULFIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES
  申请人：BAYER CROPSCIENCE AG

  公开号：US20140315898A1

  公开（公告）日：2014-10-23

  The present invention relates to novel N-arylamide-substituted trifluoroethyl sulfide derivatives of the formula (I) in which X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , n have the meanings given in the description—to their use as acaricides and insecticides for controlling animal pests and to processes and intermediates for their preparation

  本发明涉及公式（I）中的新型N-芳酰胺取代三氟乙基硫醚衍生物，其中X1、X2、X3、X4、R1、R2、R3、n的含义如描述所示—它们作为杀螨剂和杀虫剂用于控制动物害虫，并涉及其制备的过程和中间体。
• [EN] 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS DE 4-PHÉNOXYNICOTINAMIDE OU DE 4-PHÉNOXY-PYRIMIDINE-5-CARBOXAMIDE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011089099A1

  公开（公告）日：2011-07-28

  This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula (I), wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

  这项发明涉及公式（I）中的新型苯基酰胺或吡啶基酰胺衍生物，其中A1、A2、B1、B2和R1至R11如描述和索赔中所定义，并且其药学上可接受的盐。这些化合物是GPBAR1激动剂，可用作治疗疾病如2型糖尿病的药物。
• [EN] 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS D'AZÉTIDINE OU DE CYCLOBUTANE 1,3-DISUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROSTAGLANDINE D SYNTHASE HÉMATOPOÏÉTIQUE (H-PGDS)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018069863A1

  公开（公告）日：2018-04-19

  A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式（I）的化合物，其中R、R1、R2、R3、Y、Y1、a、X和Z的定义如本文所述。本发明的化合物是造血前列腺素D合成酶（H-PGDS）的抑制剂，可用于治疗杜兴氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制H-PGDS活性和治疗相关疾病的方法。
• Atom-Economical and Tandem Conversion of Nitriles to <i>N</i>-Methylated Amides Using Methanol and Water
  作者：Bhaskar Paul、Milan Maji、Sabuj Kundu

  DOI：10.1021/acscatal.9b03916

  日期：2019.11.1

  A cobalt complex catalyzed tandem conversion of nitrile to N-methylated amide is described using a methanol and water mixture. Using this protocol, several nitriles were directly and efficiently converted to the desired N-methylated amides. Kinetic experiments using H2O18 and CD3OD suggested that water and methanol were the source of the oxygen atom and methyl group, respectively, in the final N-methylated

  描述了使用甲醇和水的混合物的钴络合物催化的腈串联转化为N-甲基化酰胺。使用该方案，将几个腈直接有效地转化为所需的N-甲基化酰胺。使用H 2 O 18和CD 3 OD进行的动力学实验表明，水和甲醇分别是最终N中氧原子和甲基的来源。-甲基化酰胺。重要的是，控制实验实现了活性Co（I）–H物种参与该转化的过程。动力学同位素效应（KIE）研究表明，甲醇C–H键的活化是动力学上重要的一步。哈米特图证实了电子不足的腈的反应更快。此外，计算研究支持了从腈形成N-甲基化酰胺的可能途径。
• [EN] 9H-PYRROLO-DIPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 9H-PYRROLO-DIPYRIDINE
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2016124508A1

  公开（公告）日：2016-08-11

  The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates.

  这项发明涉及到式I的9H-吡咯-二吡啶衍生物，以及制备它们的方法、含有它们的药物组合物以及它们作为放射性药物的用途，特别是作为检测Tau聚集体的成像剂。

表征谱图